Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failed
Alimentary Pharmacology & Therapeutics2015Vol. 41(7), pp. 613–623
Citations Over TimeTop 1% of 2015 papers
Abstract
The efficacy of a second anti-TNF in CD patients largely depends on the cause for switching. The remission rate is higher when the reason to withdraw the first anti-TNF is intolerance (61%), compared with secondary (45%) or primary failure (30%). Further studies of switch ADA→IFX are needed to evaluate this strategy. PROSPERO-registry-number: CRD42014012943.
Related Papers
- Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritis.(2017)
- → Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn’s Disease(2015)9 cited
- → SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB(2017)14 cited
- → Benefit-Risk Assessment of the TNF-Antagonists Adalimumab and Certolizumab Pegol for Maintenance Treatment of Crohn's Disease(2011)
- [Place of biologic therapy in the treatment of inflammatory bowel diseases and assessment of its efficacy].(2013)